Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon, Kyoto Univ. Extend Cancer Research Collaboration
April 12, 2016
- MSD Picks Taiho as Copromotion Partner for Pembrolizumab
April 12, 2016
- Ono Fires Back to 1.75 Trillion Yen Guesstimate, Puts Opdivo Sales at 126 Billion Yen
April 12, 2016
- AC Medical to Introduce 3rd-Party Review Service for Advertising, Promotional Materials
April 12, 2016
- Companion Diagnostic for Tagrisso Now Covered by Health Insurance
April 11, 2016
- Ethical Drug Sales Jump 15.6% in February: Crecon Report
April 11, 2016
- Ex-Genzyme Japan Chief Hideyuki Ashikaga to Lead Baxter Japan
April 11, 2016
- Astellas Introduces 1st Major Reform of Domestic Marketing System in 10 Years to Understand Issues Specific to Each Area: Marketing Head
April 8, 2016
- Kaketsuken in Talks to Transfer Vaccine Biz to Astellas
April 8, 2016
- Bayer Japan Taps Big Data to Shorten Trial Site Selection by 1-2 Months; 2015 Sales Up 12.2%
April 7, 2016
- Takecab Most Promoted Drug in February: Anterio
April 7, 2016
- Terumo Preparing to Launch HeartSheet; Sees Room for Improvements in Production and Quality Control
April 7, 2016
- MSD, Alfresa, Aerosense to Collaborate in Developing a Drug Delivery Business Using Drones
April 7, 2016
- Mylan Japan Labor Union Raps Management over “Effective Dismissal”, No Progress Made in 1st Round of Negotiations
April 6, 2016
- Daiichi Sankyo Joins Portola’s Factor Xa Antidote Consortium in Japan
April 6, 2016
- Daiichi Sankyo, Asahikawa Medical Univ. to Conduct Joint Research on New Stem Cells with Funding from Mitsubishi UFJ Capital
April 6, 2016
- JT, Torii Aim to File Japan NDA for Gilead’s Anti-HIV Drug in July-September
April 6, 2016
- Astellas Strikes New Research Pact with AIST for Chagas’ Disease
April 5, 2016
- GSK Keeps Its JCR Stake at 25%, Eyes Collaboration in Blood-Brain Barrier Technology
April 4, 2016
- Asahi Kasei Pharma Licenses TrkA Inhibitors from Array BioPharma
April 4, 2016
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…